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HEMATOPOIESIS AND STEM CELLS
A far downstream enhancer for murine Bcl11b controls its T-cell
speciﬁc expression
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Key Points
• A conserved enhancer,
needed for Bcl11b expression
in early T cells and
developmentally activated in
parallel with it, lies 850 kb
downstream.
• This enhancer binds TCF-1
and loops to the differentially
methylated Bcl11b promoter
to mediate lineage-specific
activation and silencing.
Bcl11b is a T-cell specific gene in hematopoiesis that begins expression during T-lineage
commitment and is required for this process. Aberrant expression of BCL11B or proto-
oncogene translocation to the vicinity of BCL11B can be a contributing factor in human
T-ALL. To identify the mechanism that controls its distinctive T-lineage expression, we
corrected the identified Bcl11b transcription start site and mapped a cell-type–specific
differentially methylated region bracketing the Bcl11b promoter. We identified a 1.9-kb
region 850 kb downstream of Bcl11b, “Major Peak,” distinguished by its dynamic histone
marking pattern in development that mirrors the pattern at the Bcl11b promoter. Looping
interactions between promoter-proximal elements including the differentially methylated
region and downstream elements in the Major Peak are required to recapitulate the T-cell
specific expressionofBcl11b in stable reporter assays. Functional dissection of theMajor
Peak sequence showed distinct subregions, in which TCF-1 sites and a conserved
element were required for T-lineage–specific activation and silencing in non-T cells.
A bacterial artificial chromosome encompassing the full Bcl11b gene still required the
addition of the Major Peak to exhibit T-cell specific expression. Thus, promoter-proximal
andMajor Peak sequences are cis-regulatory elements that interact over 850 kb to control expression ofBcl11b in hematopoietic cells.
(Blood. 2013;122(6):902-911)
Introduction
Bcl11b is a major regulator of T-cell development and immune
functions of mature T cells. It is required from early in the CD4- CD8-
(DN) thymocyte stages. At lineage commitment, between DN2a
(Kit11 CD441 CD251 DN) and DN2b (Kit1 CD441 CD251 DN),
Bcl11b is required to repress self-renewal and alternative lineage
developmental potentials, to make the T-cell fate the only remaining
developmental choice. Deletion of Bcl11b from prethymic precur-
sors causes a developmental block at this checkpoint with extensive
proliferation possible for the uncommitted cells.1,2 The blocked
Bcl11b-deﬁcient cells have increased potential to differentiate into
Natural Killer (NK) cells and myeloid cells.1-3 Later in development
at the DN3 stage, Bcl11b is required for the ﬁnal steps of re-
combination and surface expression of TCRb.4 Bcl11b is also
essential for positive selection of both CD41 and CD81 single
positive (SP) cells and for survival of double positive (DP) cells.5
Removal of Bcl11b from mature CD81 cells results in defects in
antigen-speciﬁc clonal expansion and CD81 cell function.6 In
regulatory T cells, Bcl11b may also be involved in the development
and function of these cells by positively regulating Foxp3.7
The expression of Bcl11b is strictly T-lineage speciﬁc among
hematopoietic cells,3,8 making Bcl11b a T cell identity gene. In
the T lineage, Bcl11b is still silent in the Early T-cell Precursor
(ETP)/Kit1 DN1 stage (Kit11 CD441 CD25- DN), and only starts
to express at DN2a stage.8 After this point, the expression of
Bcl11b is detectable in every stage and every lineage of T cells.
Bcl11b is one of only a few genes in the genome with onset of
expression at this crucial stage.9
The correct triggering of Bcl11b expression inDN2a cells may also
be important for inhibiting oncogenic transformation of these rapidly
dividing cells. The earliest studies on Bcl11b identiﬁed it as a tumor
suppressor, becausemutations and deletions ofBcl11b byg-irradiation
in mouse models could result in immature thymocyte transformation,
T cell leukemia, and thymic lymphomas.10 In human T cell leukemia,
deletion and mutation of BCL11B even in heterozygous form have
been proposed to play roles in many cases of T-ALL.11-13 However,
noncoding sequences linked with the BCL11B locus may also con-
tribute to its oncogenic function.11,14,15 Studies of cancer cells from
T-ALL patients identiﬁed BCL11B as the translocation partner of TLX3
and NKX2-5 in t(5;14)(q35;q32.2) T-ALL.12,16 The translocation
actually juxtaposes TLX3 and NKX2-5 to a gene desert 39 of BCL11B
(relative to the direction of BCL11B transcription) and causes ectopic
expression of these oncogenes, leading to T-ALL. Although the
mechanism that activates TLX3 and NKX2-5 is unknown, it has been
proposed that cis-regulatory elements of BCL11B could underlie
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this oncogenic activity.14,15 Clearly the translocation enables these
oncogenes to acquire a T-cell speciﬁc enhancer, but its relationship
to BCL11B regulation has been only conjectural. Therefore, identifying
genetic inputs that activate the expression of Bcl11b in DN2a cells
will offer insight into both T-lineage commitment and oncogenesis
linked to Bcl11b.
In this report, we aimed to identify the cis-regulatory elements that
control the unique expression pattern of Bcl11b. We ﬁrst determined
the actual transcription start site (TSS) ofBcl11b in developing T cells,
mapping it within a cell-type speciﬁc differentially DNA methylated
region (DMR) of the promoter area of Bcl11b. However, this region is
insufﬁcient to promote T-cell speciﬁc gene expression. Based on cell-
type speciﬁc and stage-speciﬁc histone modiﬁcations in developing
early T cells, we discovered a 1.9-kb sequence located about 850-kb
downstream of Bcl11b that mirrored the same developmentally
regulated histone marks as the promoter of Bcl11b in early T cells.
This downstream putative cis-regulatory element was needed to
cooperate with promoter-linked and intragenic elements to drive
T cell speciﬁc expression of reporter genes in stable transfection
assays. The studies thusmap the core sequence of the Bcl11b promoter
plus a key T-cell speciﬁc downstream enhancer, providing a molecular
basis for the further understanding of Bcl11b regulation in developing
T cells and in T cell leukemia.
Materials and methods
P2C2 (SCID.adh2C2), 32D, and Raw264.7 cells were cultured and
transfected with a series of Bcl11b-sequence linked luciferase and yellow
ﬂuorescent protein (mCitrine, YFP) reporter constructs as described
herein.17,18 DNA methylation was measured by bisulﬁte-DNA-sequencing.
Major Peak (MP) mutations were generated by fusion PCR with primers
shown in supplemental Table 1 (available on the BloodWeb site). Long-range
DNA interaction wasmeasured by Chromatin Conformation Capture assay.19,20
Bacterial artiﬁcial chromosome (BAC) reporters were generated by recombin-
eering.21,22 Accession number for TCF-1 ChIP-seq data: GSE46662. Detailed
methods are given in supplemental Materials and methods. In one ﬁgure, cells
were used from mouse thymus and spleen. These animals were bred and
maintained in our colony at Caltech and were used entirely according to
Institutional Animal Care and Use Committee-approved protocols.
Results
Identification of the Bcl11b TSS
The expression pattern of Bcl11b in hematopoietic cells and its
mRNA levels in early T cells have been extensively analyzed.
Microarray (http://www.immgen.org), qPCR,8,23 and RNA-seq9
results conﬁrm that Bcl11b is a T-cell speciﬁc gene. In T-lineage
development, it starts to express in DN2a cells, and the mRNA
signals reach high levels in DN3 cells, including Rag22/2 DN3
thymocytes and DN3-like P2C2 cells. The Bcl11b promoter
region is rich in sites for regulatory inputs from Notch, Runx, and
TCF factors (Figure 1A).3,9,24-26 However, RNA-seq analysis of
early T cells9 showed that the actual start of the Bcl11b
transcripts is about 640 bp upstream of the TSS annotated in
RefSeq and the Mouse Genome Informatics Jax representative
transcript (Figure 1A). To avoid confusion on base positions,
however, in this paper we still refer to the annotated RefSeq TSS
(mm9, chr12:1009241624) as11 of the Bcl11b gene for all DNA
sequences studied here, setting the true TSS at 2640.
Promoter-spanning sequence from 2919 bp to 2332 bp at the
Bcl11b locus is a cell-type specific differentially methylated
region (DMR)
DNA methylation of CpG islands is involved in transcriptional
silencing of many developmentally important genes and can be
removed selectively at sites where cell-type speciﬁc factors exert
differential regulation.27-29 Several major CpG islands occur in the
Bcl11b locus. To identify sites that may be speciﬁcally targeted for
demethylation during T lineage-speciﬁc activation of the gene, we
measured DNA methylation across four CpG islands by bisulﬁte-
DNA sequencing. We compared P2C2 cells, which are Bcl11b-
expressing DN3-like T lineage cells, with an immature myeloid
cell line, 32D, that does not express Bcl11b. The methylation of
the CpG island encompassing the actual TSS of Bcl11b, IS2,
showed a cell-type speciﬁc pattern, highly methylated in immature
myeloid 32D cells but unmethylated in the early T-lineage P2C2
cells (Figure 1B). In contrast, the further upstream CpG island in
the 59-ﬂanking region (IS1) and the two regions in the CpG island
in exon 4 (IS3, IS4) are all highly methylated in P2C2 and 32D
cells alike. In accord with our data, Ji et al30 also found that the
Bcl11b promoter-proximal region becomes demethylated at the
DN2 and DN3 stage of T-cell development, based on a genome-wide
mapping approach (http://aryee.mgh.harvard.edu/data/charm_hsc).
Thus, the2919 bp to2332 bp region, spanning the actual promoter,
is a cell-type speciﬁc DMR for Bcl11b.
The Bcl11b promoter-DMR alone is not sufficient to drive T-cell
specific expression of reporter genes
We used the TSS-associated DMR and regions of high sequence
conservation as a starting point to map the sequences functionally
required for the T-lineage speciﬁc expression of Bcl11b (supplemental
Figure 1). Predicted sites for transcription factors likely to regulate
Bcl11b expression, positively or negatively, were also speciﬁ-
cally considered: GATA-3,31 TCF-1,26 Notch/RBPJk,3 and
PU.132 (Figure 1A). To test transcriptional regulatory function of
the DMR, we cloned candidate Bcl11b promoter regions into pGL3-
Basic, a promoter-less and enhancer-less luciferase reporter, and
measured luciferase activity after transient or stable transfections of
the vectors into P2C2 cells and Raw264.7 cells. Stable transfection
gives greater cell-type speciﬁcity in gene regulation, more robust
results, and greater dynamic range than transient transfection using
these cell lines.17,18 In this assay, constructs beginning at the an-
notated Bcl11b promoter (supplemental Figure 3: PR1 and PR2)
were inactive in both P2C2 and Raw264.7 cells. However, even
with the Bcl11b DMR and true TSS included (PR3), the promoter
lacked activity. Further analysis of the 10-kb DNA sequence
upstream of Bcl11b identiﬁed three conserved regions (supple-
mental Figure 1A: CS1, CS2, and CS3). These conserved sequences
were cloned into pGL3-Basic reporter with the Bcl11b DMR-
promoter in different combinations and tested in P2C2 and
Raw264.7 cells. However, as shown in supplemental Figure 2 and 3,
none of these constructs activated luciferase in a T-cell speciﬁc way,
suggesting that elements from the 59-ﬂanking region of Bcl11b are
not sufﬁcient to recapitulate the Bcl11b expression pattern.
The 5-kb 39-UTR of Bcl11b is one of the most conserved
regions on mouse chromosome 12, and it is predicted to be a target
of several microRNAs (supplemental Figure 4A). To test whether
mRNA stability regulated by miR-39-UTR interaction contributed
to the cell-type speciﬁc regulation of Bcl11b, the Bcl11b 39UTR
was cloned into the pGL3-Control vector into the 39 untranslated
region of the luciferase reporter (supplemental Figure 4B), and was
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tested by stable transfection into P2C2 and Raw264.7 cells.
However, inclusion of the Bcl11b conserved 39-untranslated
sequences did not increase the T-lineage speciﬁcity of expression,
as it did not speciﬁcally reduce luciferase expression in the non-T
Raw264.7 cells (supplemental Figure 4C).
A downstream region shares with the Bcl11b promoter
developmental stage-specific and cell-type specific histone
modification marks
As these elements in or near the Bcl11b locus were insufﬁcient
to recapitulate its expression pattern, we searched for potential
cis-regulatory elements in a larger area. There is a 2-Mb gene
desert downstream of Bcl11b, relative to the direction of Bcl11b tran-
scription, without any annotated protein-coding genes. Further up-
stream of Bcl11b, by contrast, are multiple constitutively expressed
genes, separated from the Bcl11b locus even in Bcl11b-expressing
T-lineage cells by a block of chromatin with H3K27me3 marks,
suggesting polycomb-complex mediated repression or barrier func-
tion.9 We therefore sought loci across the downstream gene desert
where histone modiﬁcation marks H3Ac, H3K4me2, and H3K27me3
might correlate developmentally with those on the Bcl11b locus
itself. A 1.9-kb region ;850 kb downstream of Bcl11b was the most
Figure 1. Identification of transcription start site and a differentially methylated region in the 59-flanking area of Bcl11b. (A) RNA-seq on early T cells identified the
actual TSS (red) of Bcl11b transcripts, which is about 640 bp upstream of the annotated one (blue). RNA-seq data from ref. 9, transcription factor binding sites from refs. 3, 9,
24-26. (B) The DNA methylation of three CpG islands on the Bcl11b locus was measured by bisulfite-DNA sequencing. IS1, CpG island 1. IS2, CpG island 2. IS3 and IS4,
2 representative regions on CpG island 4. Because of technical issues, the methylation of an additional CpG island in intron 2 was not analyzed. The closed dots represent
methylated CpG sites, and the open dots represented unmethylated sites. The positions of the CpG islands are relative to the annotated TSS of Bcl11b.
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signiﬁcant T-lineage histone modiﬁcation peak in this 2-Mb gene
desert. Conspicuously, this “Major Peak” shares the same histone
modiﬁcation marks as the promoter region of Bcl11b, not only in
cell-type speciﬁcity, but also in the dynamics of developmental
activation (Figure 2).9 In DN1 stage, before cells turn on Bcl11b,
Bcl11b promoter chromatin lacks histone H3Ac or H3K4me2, but
is enriched for the repressive mark H3K27me3. In DN2b cells,
which express high levels of Bcl11b, the promoter shows high
levels of H3Ac and H3K4me2, whereas H3K27me3 is speciﬁcally
removed. In parallel, the active histone marks on Major Peak
increase from DN1 to DN2b, whereas the repressive histone marks
decrease (Figure 2A). Comparing the histone marks on Bcl11b and
Major Peak regions in different hematopoietic cells, we found
H3Ac on Bcl11b promoter and Major Peak speciﬁcally restricted
toBcl11b-expressing T cells, whereas the repressivemarkH3K27me3
was concentrated on both regions in cell types that do not express
Bcl11b, such as pre-proB cells (Figure 2B).33 In human mature
CD41 T cells with BCL11B expression, the histone marks on
Major Peak also mirror those on BCL11B locus (supplemental
Figure 5).34 H3K4Me1, an enhancer-associated histone mark, was
well enriched on the Major Peak locus in human CD41 T cells, but
not in human cell lines without BCL11B expression (ENCODE
lines Gm12878 and H1 ES cells) (supplemental Figure 5).35 An
EST or LincRNA from this region has been reported (Gm16084).
However, tissue speciﬁc enhancers are often sites of low-level
RNA transcription correlated with activity.36
Chromatin conformation capture identifies direct T-lineage
specific interactions between the Bcl11b promoter and Major
Peak regions
We tested whether Major Peak physically interacts with Bcl11b in
early T-lineage cells using chromatin conformation capture (3C)
assays (Figure 3A). A series of forward primers was designed across
the Bcl11b locus with a series of reverse primers spanning the Major
Peak (Figure 3B; sequences in supplemental Table 1). As negative
controls, we evaluated interaction between sequences around the
Major Peak and its neighbor on the opposite site, Vrk1, between
Major Peak and the coinduced T-cell speciﬁc Cd3gde gene cluster,
and between Bcl11b and known cis-regulatory elements of the
Sfpi1 locus (supplemental Figure 6). The assays identiﬁed several
interactions between the Bcl11b promoter and ﬁrst intron region
(F3) and the Major Peak (R4), with possible additional contacts
involving the 59 ﬂanking region of Major Peak (R3) and ﬁrst intron
sequences of Bcl11b near a second major TCF-1 binding peak (R5).
In contrast, interactions between Major Peak and Vrk1, between
Major Peak and Cd3gde, and between Bcl11b and Sfpi1, were at
levels similar to background controls with unligated DNA (supple-
mental Figures 6 and 7; Figure 3A). The interactions between Bcl11b
and Major Peak were considerably stronger in T-lineage cells than in
myeloid or nonhematopoietic cells (Figure 3A, P , .02, Mann-
Whitney U test), and T-cell speciﬁc interactions were hinted also
to involve sequences in Bcl11b intron 3 (F14-18), another site of
expression-linked histone marking.9 Apparent lineage-nonspeciﬁc
interactions at particular sites, for example, between F5 and R5, could
be traced to cross-reactions of speciﬁc pairs of primers with other loci
in genomic DNA (see supplemental Methods). Thus, despite the 850-
kb separation, a structural basis exists in T-lineage cells to allow
Major Peak to participate in Bcl11b transcriptional regulation.
The Major Peak is a T-cell specific enhancer of Bcl11b
To determine whether Major Peak interacts functionally with the
Bcl11b promoter, we tested its impact on activity of other possible
Bcl11b regulatory sequences. Starting with a pGL3-Basic construct
with the DMR-promoter region (PR3) driving expression of
luciferase (supplemental Figure 3), the Major Peak sequence was
inserted, downstream of the SV40-poly(A) addition site of the
luciferase reporter, to rule out any activity that it might mediate as an
alternative promoter (Figure 4A). The Major Peak also covers only
a 59 fraction of the region transcribed into Gm16084, so that any
regulatory functions that might be mediated through the full
noncoding RNA transcript itself would not be supported either.
Stable transfection of these constructs into two T cell lines, P2C2
and EL4, now yielded high expression levels of luciferase reporter,
at least 10-fold higher than expression from PR3 promoter alone,
and comparable to the levels of the construct with a positive control
enhancer (pGL3-Control) (Figure 4B). In contrast, when the
constructs were stably transfected into two non-T cell lines, the
macrophage Raw264.7, and the pre-B NFS25 cells, the Major Peak
did not enhance the expression of luciferase reporter above the basal
levels from the PR3 promoter alone. Furthermore, Major Peak could
activate T-lineage expression from PR3 but not from PR1, the
annotated promoter lacking the DMR, or from an SV40 promoter
(Figure 5). Thus, the Major Peak confers T-lineage transcriptional
activity speciﬁcally on the Bcl11b promoter-DMR.
Both ends of the Major Peak sequence are highly conserved, and
ChIP-seq results showed that Runx1, TCF-1, Ikaros, PU.1, and
GATA-3 bind to the conserved end of Major Peak with promoter-like
Figure 2. Histone modifications identify a far downstream Major Peak that
shares with the Bcl11b promoter its patterns of histone marks. (A) Distinct
epigenetic modification and gene expression patterns at the genomic region
spanning Bcl11b and several downstream and upstream gene loci in T-cell
precursors from DN1 to DN2b.9 Black arrow: Major Peak. The Major Peak
displays similar dynamics of epigenetic modifications as Bcl11b. H3Ac: blue,
H3K4me2: red, H3K27me3: green, RNA-seq: black. (y-axis units in RPM). (B)
Epigenetic modification patterns at the same genomic region in EBF2 /2 pre-pro
B cells.33
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histone marks (“59”), whereas TCF-1 also binds to another, central
site pair (Figures 5A and 69,24,25,37). To determine which subregions
are functional, constructs were made with serial deletions of Major
Peak (Figure 5B, MP-F1, MP-F2, etc.). None of the constructs
missing either end of Major Peak (PR3-MP-F1, PR3-MP-F2, PR3-
MP-F3, and PR3-MP-F4) could recapitulate the expression pattern
of PR3with the intactMajor Peak in stable transfection experiments.
They poorly enhanced expression in P2C2 cells, showed high inter-
culture variability, and gave equal expression in Raw264.7 cells.
However, the PR3-MPFusion, which deletes a 528-bp sequence
between the two TCF-1 binding peaks, mediated full MP function. It
promoted reporter expression consistently at levels comparable to
that of PR3-MP and pGL3-Control in P2C2 cells, while silencing
expression in Raw264.7 cells (Figure 5B). Even with the 59 region
intact, deletion of the centrally located TCF-1 sites (dmTCF), or
deletion of the 39 conserved region (MPF5), was sufﬁcient to cancel
Figure 3. T-cell specific chromatin looping between
Bcl11b and the downstream Major Peak. (A) Chroma-
tin conformational capture was performed on samples
from T-lineage cells (B6 thymocytes, Rag12/2 or Rag22/2
thymocytes, P2C2 cells) and non-T cells (Rag12/2 or
Rag22/2 splenocytes, Raw264.7 cells and NIH3T3 cells)
to measure the physical interactions between Bcl11b and
Major Peak regions. Rag-knockout thymocytes were
included as naturally arrested DN3 thymocyte popula-
tions, the in vivo equivalent of P2C2 pro-T cells. Panels
show the PCR signals resulting from linkage between the
R3, R4, and R5 primers within the Major Peak region and
the indicated forward primers spanning the Bcl11b
promoter and first two introns. For schematics and con-
trols, see supplemental Figures 6 and 7; sequences
presented in supplemental Table 1. P values for cell-type
specificity were calculated by Mann-Whitney U test,
comparing the five independent T-lineage samples with
the four indicated non-T samples; *P , .02. The lineage
nonspecific R5-F5 signal is caused by a background
anomaly with this specific primer combination. Addi-
tional negative controls, samples of normal and Rag-
knockout thymocytes processed for 3C without addition
of ligase (“unligated”), are shown for reference. (B) Map of
positions of primers used.
Figure 4. Major Peak drives T-cell specific expres-
sion of luciferase in stable transfection assays. (A)
The PR3 sequence of Bcl11b promoter region and
Major Peak were cloned into the pGL3-Basic vector. (B)
pGL3-Basic, pGL3-Control (SV40-PR; SV40-En), PR3,
PR3-MP constructs were stably transfected into Raw264.7,
NFS25, P2C2, and EL4 cells with pTracer-Renilla lucifer-
ase construct. The firefly luciferase activities were
normalized to Renilla luciferase activities. The Normal-
ized Expression was calculated by designation of the
geomean of pGL3-Basic as 1 unit. •, relative firefly
luciferase activities normalized by Renilla luciferase activ-
ities. -, geomeans of the data points in the same sample.
Data shown are from one experiment representative
of 3.
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enhancer activity (Figures 5C and 6). This implies functional re-
quirements for at least three subregions, comprising two conserved
terminal blocks and at least one additional region of TCF-1 binding.
Major Peak can thus cooperate with the promoter-DMR region to
provide both lineage-speciﬁc enhancer and silencing functions. Still, it
is possible that intron 1 and intron 3 of Bcl11b might also contain
intragenic cis-regulatory elements3,9 (Figures 1A and 3), and other
regions in or around the Bcl11b locus might assist its regulation.26
Therefore, to testwhether theMajor Peak is required for T-cell speciﬁc
regulation in the context of a full complement of intragenic and
promoter-associated elements, wemeasured the functional effects of
Major Peak when added to a whole-locus Bcl11b BAC. A YFP
reporter was knocked into exon 1 of Bcl11b, in a 193-kb BAC
that spans the Bcl11b locus from 31.8 kb upstream to 56.6 kb
downstream (Figure 7A). This BAC-Bcl11b-YFP construct expresses
no Bcl11b protein but preserves all required intragenic elements for
Bcl11b expression, since a knock-in mouse with a reporter in this site
showed the correct Bcl11b expression pattern in hematopoietic cells
(HYK and EVR, to be reported elsewhere). The 1.9-kb Major Peak
was further cloned into the BAC, 9.8-kb downstream of Bcl11b, to
generate the BAC-Bcl11b-YFP-MP construct. The 2 constructs with
and without Major Peak were then compared for the ability to drive
YFP expression on stable transfection into T-lineage P2C2 and
myeloid-lineage Raw264.7 cells.
Figure 7B shows YFP expression levels in 6 parallel stably
transfected subcultures with each construct in each of the 2 cell
lines. The BAC-Bcl11b-YFP construct, although it covers the
entire Bcl11b locus, did not promote any YFP expression in either
Figure 5. TCF-1 binding sites are essential cis-
regulatory elements for the activity of Major Peak.
(A) The structural framework of constructs used in the
stable transfection assays. Stars, mutated TCF sites
in dmTCF construct; triangles, major peaks of TCF-1
binding as shown in Figure 6. (B) Constructs with PR1
or PR3 promoters and serial deletions of the Major
Peak (in a downstream enhancer position) were made
as shown schematically. The major TCF-1 binding
peaks in MP are marked for reference (coordinates of
construct end points provided in supplemental Table 2).
Note that the CAAAG/CTTTG motifs that presumably
nucleate the second TCF-1 peak are just beyond the
boundary of MP-fragment 2. Graph shows normalized
luciferase expression in 8 parallel cultures with each
construct, stably transfected into P2C2 (red) and
Raw264.7 (blue) cells after two weeks of selection.
The same results were seen for these constructs in
2-3 independent experiments. (C) Either specific
deletion of the two central TCF-1 binding sites or
removal of the 39 conserved region (MPF5) de-
creases the enhancer activity of Major Peak in P2C2
cells. dmTCF, the construct with double mutation
(deletion) of TCF-1 binding peaks shown in Figure 6.
MPF5, truncated construct lacking 39 conserved region.
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T cells or myeloid cells. In contrast, the construct with Major
Peak, BAC-Bcl11b-YFP-MP, expressed YFP in 5/6 T-lineage cell
subcultures, whereas none of the myeloid cell subcultures had YFP
expression. To verify the presence of stably transfected BAC
DNA, YFP copy number was measured by qPCR in genomic
DNA from each subculture. There was some minor copy number
variation (supplemental Figure 8), but the YFP-transfected cultures
without YFP expression had at least as many copies of YFP DNA
integrated into chromosomes as the subcultures with expression of
YFP, yet only those with Major Peak in T cells expressed. Thus,
though the cis-regulatory sequences within the Bcl11b locus might
play some roles in the regulation of Bcl11b expression, they were not
powerful enough to drive expression in this system without Major
Peak. These results imply that Major Peak confers an essential, rate-
limiting function for T-lineage speciﬁc expression of Bcl11b.
Discussion
Bcl11b is one of only a few T-cell speciﬁc regulatory genes with
highly stage-speciﬁc onset of expression during commitment.
Uniquely among hematopoietic lineages, Bcl11b is turned on in
T-cell precursors at DN2a stage and maintained through all later
stages, and it is required for lineage commitment, viability, and
T-cell function starting almost immediately after it is turned on. In
this paper, we have identiﬁed two regulatory regions that cooperate
to control this expression. First, we have corrected the location of the
promoter and shown that it is embedded in a CpG island with
cell-type–speciﬁc differential DNA methylation. In T-lineage
cells speciﬁcally, we have shown that this promoter-DMR region
interacts functionally with the second element, an extremely
distal 1.9-kb sequence .850 kb downstream of the gene, which
was mapped originally based on its dynamic and highly cell-type
speciﬁc pattern of histone marks in developing T cells. This
“Major Peak” region also interacts speciﬁcally with the Bcl11b
locus, especially in T-lineage cells. It proves to be a bipartite cis-
regulatory element that confers both lineage-speciﬁc positive and
negative regulation, speciﬁcally in cooperation with the full
promoter-DMR. The results suggest that the downstream Major
Peak is an essential cis-regulatory element that activates Bcl11b
expression in early T cells.
Besides T cells, Bcl11b is expressed in the central nervous system
and in skin cells as well. Precedents from the SCL gene indicate that
different cis-regulatory elements are likely to promote expression of
the same gene in such different tissues.38 Although noncoding se-
quence conservation implies likely function, it might not be sufﬁcient
to identify the cis-regulatory elements needed by Bcl11b speciﬁcally
in T cells. We therefore focused on regions where T-lineage-speciﬁc
activity could be indicated by epigenetic clues. Lineage-speciﬁc
demethylation of the promoter-DMR, in contrast to three other CpG
islands around the Bcl11b locus, implied that it may be an important
target of cell-type speciﬁc transcription factor action. Indeed, the
DMR is required to enable the Bcl11b promoter to cooperate with
the Major Peak in stable transfection assays. Lineage-speciﬁc histone
marking dynamics enabled us to locate the Major Peak.
Our results leave open possible roles for intragenic cis-regulatory
elements, which were not systematically tested here. The ﬁrst intron
of Bcl11b is likely to contribute, since activating histone marks
appear here,9 TCF-1 binds strongly (Figure 1), and binding of the
Notch-dependent transcription factor CSL has also been described.3
Intron 3 may also play a role. In our assays, the CpG islands con-
tained within exon 4 did not show methylation differences between
T and non-T cells. However, the CpG “shore” of this CpG island,
Figure 6. Transcription factor binding sites and
histone modifications on the Major Peak. The binding
profiles of Runx1, TCF-1, Ikaros, PU.1, and GATA-3 at
the Major Peak region in T cells, measured by ChIP-seq,
are shown.9,24,25,37 Also shown are the alignments of the
full MP sequence and the 528-bp region between the two
TCF-1 binding peaks, which was deleted from Major
Peak to make the MPFusion construct. Dark blue stars
mark the two central TCF-1 sites that were mutated in
the dmTCF construct. The 39 conserved region is also
indicated. For coordinates, see supplemental Table 2.
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located in intron 3 immediately upstream of Exon 4, may also be
speciﬁcally demethylated in Bcl11b-expressing T cells30 and has
T-cell speciﬁc H3K4me2 marking from the DN2b stage onward.9
Nevertheless, our BAC transfection assays showed that a BAC-
Bcl11b-YFP construct that includes all of these intragenic sequences
along with substantial 59 and 39 ﬂanking sequence still did not
express the YFP reporter, unless Major Peak was present as well.
Thus, although intragenic Bcl11b cis-regulatory elements may affect
Bcl11b levels or play a role in initial developmental activation, they
do not replace the requirement for Major Peak to drive the T-cell
speciﬁc expression of Bcl11b in early T lineage cells.
Major Peak contains sites for positive regulatory inputs that have
been implicated in activation of Bcl11b, including TCF-1 and Runx1
as well as a weaker site for GATA-3. Interestingly, two separate
subelements within Major Peak appear to be needed for its activity,
each including TCF-1 sites and a highly conserved region. The T-cell
speciﬁc positive regulatory activity is coupled tightly with a locus
control region-like effect on consistency of expression, and also with
a lineage-speciﬁc silencing effect on expression in myeloid cells,
perhaps required because of the ability of PU.1 to bind to this element
as well. This suggests a more complex cis-regulatory function of
Major Peak than a simple enhancer.
A mechanism that may promote the interaction of Major Peak
with the Bcl11b locus across 850-kb is suggested by the binding
pattern of CTCF, a mediator of chromosome looping in its roles both
to deﬁne domain boundaries and to mediate enhancer-promoter
collaboration.39,40 In both Bcl11b-expressing and nonexpressing
cells, CTCF binding sites are profuse upstream of Bcl11b and down-
stream of the Major Peak. A constitutive CTCF binding peak is also
present in Bcl11b intron 1. However, the ﬁrst CTCF site downstream
of Bcl11b is just beyond Major Peak (supplemental Figures 5 and 9).
Hi-C assays detect a chromatin interaction topological domain with
one boundary on Bcl11b and the other boundary just beyond Major
Peak41 (supplemental Figure 9). This topological domain is conserved
across species and cell types irrespective of Bcl11b expression. Thus,
chromatin interactions between the Major Peak and Bcl11b loci could
be maintained by CTCF constitutively, thus creating a permissive
framework for the cell-type speciﬁc regulation of Bcl11b.
In many cases of human T-ALL, translocations of t(5;14)(q35;
q32.2) juxtapose TLX3 and NKX2-5 to the BCL11B downstream gene
desert, and cause ectopic expression of these oncogenes leading to
T-ALL. Strikingly, the translocation break points at the BCL11B locus
spread over .800-kb downstream of BCL11B, but end with a clear
boundary right on the Major Peak (supplemental Figure 10). It has
been speculated that sequences around that boundary contain cis-
regulatory elements that are able to drive the expression of TLX3 and
NKX2-5 in immature T cells,14 in particular DNase hypersensitive
sites characterized by Nagel and coauthors.15 The Major Peak may be
the cis-regulatory element that activates the oncogenes in t(5;14)(q35;
q32.2) T-ALL. However, there is a further implication if this element
is a key regulator of BCL11B. The translocation would not only create
a gain of function of TLX3 or NKX2-5 in T cells, but also break the
connection between BCL11B and a needed cis-element, and this
would be predicted to cause some loss of Bcl11b function as well.
Although a translocation may only affect one allele of BCL11B, an
emerging consensus is that BCL11B is haploinsufﬁcient as a tumor
suppressor. Frequently, it appears most dangerous for oncogenesis
when it is present in only one copy—enough to sustain T-lineage
viability but not to prevent transformation10-12,42,43 Thus these trans-
locations that separate Bcl11b from Major Peak may promote
oncogenesis by two mechanisms at once.
Extremely long-range tissue-speciﬁc cis-regulatory elements such
as Major Peak are difﬁcult to study. The longest-distance cases before
this were discovered by mutational serendipity: for example, ZRS, the
limb bud-speciﬁc enhancer of sonic hedgehog (Shh), located within
intron 5 of Lmbr1, a gene about 1-Mb upstream of Shh.44 A tissue-
speciﬁc chromatin interaction between Shh and its enhancer ZRS
activates its expression in the limb bud-forming cells,45 similar toMajor
Peak interaction with Bcl11b. Several central nervous system speciﬁc
Shh enhancers were also identiﬁed located across the 700-kb gene
desert upstream of Shh.46 Other examples include the T/NK cell
speciﬁc enhancer of Gata3, 280-kb away,47 and the 1-Mb upstream
enhancer of Sox9 to control sex determination.48 These latter cases,
like Bcl11b, involve a gene ﬂanked by a gene desert of hundreds
of kilobases or more, containing tissue-speciﬁc enhancers.
Adding to these precedents, our study emphasizes the need to
search for megabase scale cell-type speciﬁc chromatin inter-
actions to identify cis-regulatory elements, and illustrates
a strategy that can be used to ﬁnd them.
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